INTRODUCTION
Primary palmar hyperhidrosis can cause occupational, social, and emotional problems that affect physical and mental well-being and usually lead to diminished quality of life [1] .
Two of the treatment options currently considered as being most effective for this condition are periodical local injections of botulinum toxin and endoscopic thoracic sympathectomy (ETS) [2, 3] . At present, there are no guidelines for the clinical use of these treatment modalities for palmar hyperhidrosis. In most cases, botulinum toxin and ETS are contemplated only when the less invasive medical treatments, such as topical or systemic medications (including glycopyrrolate and clonidine) and iontophoresis, have failed to provide adequate control of hyperhidrosis [4] [5] [6] [7] [8] .
Studies directly comparing the effectiveness of botulinum toxin and ETS for palmar hyperhidrosis are scarce [9] . Recently, our group has observed that ETS is superior to botulinum toxin in the treatment of palmar hyperhidrosis in terms of efficacy and patient satisfaction, particularly in subjects with baseline severe palmar hyperhidrosis [10] . However, as yet there are no published studies that analyze the economic impact of both treatments. We believe that such an analysis is necessary, particularly because of the high cost associated with both treatments. Regardless of perspective, the objective of such an evaluation would be to provide information on the clinical and economic consequences related to these therapeutic alternatives faced by patient/ physician. From an economic standpoint, an outcomes analysis may provide general evidence that could guide future research efforts by identifying decision-critical parameters that help to indicate the best way to treat palmar hyperhidrosis. Therefore, the aim of this study was to evaluate the cost (expressed in monetary terms), with regard to efficiency and patientreported outcomes, between botulinum toxin and ETS in the treatment of palmar hyperhidrosis in a real-world scenario.
MATERIALS AND METHODS

Population and Design
Following a retrospective and observational design, an economic evaluation was performed comparing the cost-efficacy of botulinum toxin 
Evaluation of Effectiveness and Patient Satisfaction
Effectiveness was evaluated by estimating hyperhidrosis severity at baseline and after treatment using the Hyperhidrosis Disease Severity Scale (HDSS) [11] . The patient is asked to select the statement that best reflects his or her experience with sweating of the specified body area ( hyperhidrosis. Post-treatment, as part of a subjective efficacy evaluation and patient satisfaction, the HDSS is administered again.
An improvement of 1 or 2 points on the HDSS scale represents a reduction in sweat production 
Statistical Analysis
The normality of the data was assessed using the Shapiro-Wilk test; logarithmic transformation was used when variables did not have a normal distribution. To check for differences between the two treatment groups, the Chi-square test was used for qualitative variables and the Student's t test for quantitative variables. All the data presented in the text, tables, and graphs are expressed as mean and standard deviation (SD), unless otherwise specified. We considered a 95% confidence interval for the mean and a P value of less than 0.05 as statistically significant. All tests were performed with different packages of the R statistical programming environment (GNU) [12] .
All procedures were performed in accordance with the ethical standards of the responsible committee on human experimentation and with the Declaration of Helsinki of 1975.
Informed consent was obtained from all the patients included in the study. 
Descriptive Temporal Analysis
The temporal analysis of efficacy, satisfaction, security, and costs by year over the first 5 years of use of both treatments in our hospital is shown in Tables 5 and 6 (Fig. 1) .
Incremental Cost-effectiveness Analysis
In the course of the 5-year study period, total costs associated with palmar hyperhidrosis treatment at Reina Sofia University Hospital were € 178,704.00 for botulinum toxin and € 144,896.00 for ETS (Tables 5, 6 ). There are statistically significant differences in the reduction of HDSS and degree of satisfaction when botulinum toxin is compared with ETS (all P\0.05) ( Table 4 ). The incremental cost per additional responder following treatment with botulinum toxin was € 125 higher than after ETS during the first year ( Table 7) . As the number-needed-to-treat (NNT) value shows, four patients have to be treated with botulinum toxin to obtain the same rate of effectiveness that is achieved with ETS (Table 8) . 
DISCUSSION
In our study, ETS for palmar hyperhidrosis appears to be more effective and less costly than botulinum toxin during the first year of treatment. Botulinum toxin was associated with higher total costs and less effectiveness than ETS in a 5-year palmar hyperhidrosis treatment program in our hospital. When cost/HDSSdif and cost/satisfaction ratios are evaluated over 5 years, ETS-associated cost/satisfaction and botulinum toxin-associated cost/HDSSdif were the lower and the higher values, respectively. Cost/HDSSdif and cost/satisfaction ratios represent how much money, on average, is required to improve one unit of HDSS or to increase one level in the satisfaction scale, respectively, per patient and year, for each modality of treatment. Hence, we may conclude that increasing the satisfaction of these patients by ETS is the cheapest strategy, and that the most expensive approach is to reduce sweating severity by means of botulinum toxin injections. Considering that four patients have to be treated with botulinum toxin to obtain the same rate of effectiveness that is achieved with ETS, and that the ICER for botulinum toxin was € 125, this gives a potential saving of € 3,125 if ETS had been chosen by all patients. This saving accounts for 2.93% of the ETS-associated total cost during the first year of the study. One of the benefits of using real-world data is that they can provide estimates of long-term effectiveness in a variety of typical practice settings when multiple alternative interventions or clinical strategies are compared in a diverse study population, which reflects the range and distribution of patients observed in clinical practice [13] . This standardized, multi-center, prospective study. Secondly, the initial and final measurement of the severity of hyperhidrosis was made retrospectively, thus raising the possibility of a recall bias. However, since hyperhidrosis is a lengthy process with an evolutionary period of over 10 years in most cases, we believe that patients recall the effects produced by palmar hyperhidrosis before and after they underwent treatment with sufficient precision.
One other potential shortcoming of our study was excluding costs arising from the management of adverse reactions associated with each treatment. A treatment may be more expensive, but by being more effective or involving less complications/sequelae, it may be preferable for the patient. We consider necessary that patient should take into account this vital information when choosing one of these therapeutic options. In the group of patients treated with ETS, both patient satisfaction and efficacy were clearly conditioned by the occurrence of compensatory hyperhidrosis (CH). CH is the most common side effect of ETS, as well as the most disabling side effect when it is severe [14] . The fact that the efficacy of this procedure is conditioned by the severity of CH, when the two measures should be independent, helps to explain the impact of this side effect on subjects who undergo surgery. These patients would probably be willing to accept this side effect if it were offset by a significant improvement in palmar hyperhidrosis. This could explain why greater satisfaction is seen in this group despite the higher incidence of CH after ETS. The frequency of the rest of the adverse reactions, such as pain, weakness, or hematoma was minor, mostly transitory, and with difficult-toestimate derived costs. In summary, our data suggest that when considering therapeutic options for palmar hyperhidrosis, ETS may offer greater efficacy, greater patient satisfaction, and lower direct cost than botulinum toxin. In the virtual absence of similar economic studies, this study can be used as an additional source of information for placing both options within the scope of the Spanish National Health System.
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